FDA has issued warning letters to three companies for marketing adulterated and misbranded COVID-19 antibody tests.
New data from TERAVOLT, a global consortium that tracks outcomes of people with thoracic cancers affected by COVID-19, could demonstrate why thoracic cancer patients experienced a high death rate of 33% when COVID-19 swept across Europe.
Mount Sinai Health System is beginning the first clinical trial in the New York metropolitan region of an immune-boosting therapy in COVID-19 patients.
Early in the War Against Cancer, when huge amounts of federal funds were suddenly funneled into cancer research, many scientists and clinicians working in other fields suddenly found it convenient—if not essential—to incorporate cancer into the title of their grant applications.
The American Cancer Society has raised $160 million so far this year, an astonishingly low number for an organization that historically has booked about half of its funds from walks, runs, and relays that take place in the spring and early summer.
The COVID-19 pandemic will likely cause at least 10,000 excess deaths from breast cancer and colorectal cancer over the next 10 years in the United States.
The Cancer Letter received five 2020 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists:
Opdivo (nivolumab) was approved by FDA for patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based chemotherapy.
Nyvepria (pegfilgrastim-apgf), a biosimilar to Neulasta (pegfilgrastim), received FDA approval.
Berubicin was granted Orphan Drug Designation by FDA for the treatment of malignant gliomas.
